DEPARTMENT OF HEALTH AND HUMAN SERVICES Monitoring Anthrax Vaccine Adverse Events Defense Medical Surveillance System (DMSS) Michael McNeil, MD, MPH National.

Slides:



Advertisements
Similar presentations
The Vaccine Adverse Event Reporting System: A Tool for Safety and Surveillance Jane Woo, MD, MPH Vaccine Safety Branch Division of Epidemiology Office.
Advertisements

Adverse Event Reporting: Getting started Lynn Bahta, R.N., B.S.N Minnesota Department of Health August 2008.
VACCINE SAFETY: 101 Pandemic Influenza Vaccine Safety Conference Atlanta, Georgia August 21, 2008.
The Brighton Collaboration: An Overview and Preparedness for Pandemic Influenza Jane Gidudu MD, MPH Team leader April Compingbutra MPH, Paige Lewis MPH.
Christa-Marie Singleton, MD, MPH Associate Director for Science
Partners in Data Recovery and Reporting Jeanne Spears, RN Disaster Health Services 0.
Overview of Terrorism Research at the CDC Dixie E. Snider, M.D., MPH. Associate Director for Science Presented at 2003 Medical Research Summit March 6,
David A. Gerber, MD Professor and Chief Division of Abdominal Transplantation Department of Surgery University of North Carolina at Chapel Hill.
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
ETIM-1 CSE 5810 CSE5810: Intro to Biomedical Informatics Mobile Computing to Impact Patient Health and Data Exchange and Statistical Analysis Presenter:
Patient Safety and Public Health Informatics Iona Thraen, ACSW Patient Safety Director.
Mary Ann Laviolette, Ethics Coordinator Ottawa Hospital Research Ethics Board (OHREB) and University of Ottawa Research Ethics Board (HREB)
Capability Cliff Notes Series PHEP Capability 14—Responder Safety and Health What Is It And How Will We Measure It?
Lisa Denney, MPH HRPP Assistant Director Melanie Mace, MA HRPP Education and Training Coordinator Bill Woods, PhD CAPS Policy and Ethics Core November.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
The National Vaccine Plan Process - Update October 22, 2007 Raymond A. Strikas, MD National Vaccine Program Office Department of Health and Human Services.
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
Yesterday, today, and tomorrow
Veterans Exposure Concerns: The Occupational and Environmental Medicine History Debra Milek M.D., Ph.D., M.P.H. Department of Preventive Medicine/Occupational.
Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress James D. Cross, M.D. National Head Medical Policy and Program Administration.
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 31 Health Supervision.
1 LYMErix® Safety Data Reported to the Vaccine Adverse Event Reporting System (VAERS) Robert Ball, M.D., M.P.H., Sc.M. Division of Epidemiology Office.
Examples of ADE Surveillance Systems MedDRA ® Processing of Adverse Event Reports in ADE Surveillance Systems Amarilys Vega, M.D, M.P.H., Sonja Brajovic,
DEPARTMENT OF HEALTH AND HUMAN SERVICES Monitoring Anthrax Vaccine Adverse Events Defense Medical Surveillance System (DMSS) Michael McNeil, MD, MPH National.
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.
Services for occupational health.  Under the Ministry of Health, an institute is being develop for medical research purposes. It is INSTITUTE for MEDICAL.
ICD-10 Transition: Implications for the Clinical Research Community Jesica Pagano-Therrien, MSN, RN, CPNP HRPP Educator UMCCTS Office of Clinical Research.
1 DoD Smallpox Vaccination Program Policy – Training – Standards – Communication – Safety Assurance – Safety Assessment Science – Quality – Confidence.
1 ESSENCE: Biosurveillance in Support of the DoD Health Mission.
California Stroke Registry Right Care Initiative Meeting August 13, 2012.
Vaccine Safety Working Group Update NVAC Meeting June 2, 2010 Tawny Buck Co-Chair, Vaccine Safety Working Group.
The Research Subject Advocate (RSA). Pictured, left to right: Andrea Saltzman, RN; Enrico Cagliero, MD; Debi Dunkless.
Abbreviated Donor History Questionnaire: Background and Introduction Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee March 2005.
1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.
9/8/2008Neumar - Emergency Care Research1 Emergency Care Research Solutions for the U.S. Heath Care System Robert W. Neumar MD, PhD Chair, Research Committee.
(Slide 1 of 22) Response to the National Vaccine Advisory Committee Recommendations on the Immunization Safety Office Scientific Agenda Frank DeStefano,
The National Electronic Injury Surveillance System: Cooperative Adverse Drug Events Surveillance System (NEISS-CADES) Aaron B. Mendelsohn, PhD, MPH Office.
Western Node Collaborative RIVERVIEW HOSPITAL Medication Reconciliation Project Phase One: Admitting June 19, 2006 Zaheen Rhemtulla B.Sc. (pharm)
NVAC Influenza Vaccine Recommendations and Strategies Subgroup Members: Jerome Klein (Chair), Jeff Davis, Jon Abramson, Carolyn Bridges, Nancy Cox, Ben.
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
NVAC H1N1 Vaccine Safety Risk Assessment Working Group (VSRAWG) Update NVAC Meeting June 2, 2010 Marie McCormick, M.D., Sc.D. Sumner and Esther Feldberg.
Plans to Assess the Effectiveness of Seasonal and Pandemic Influenza Vaccines during David Shay MD, MPH (Prevention Assessment and Modeling Team.
David A. Gerber, MD Professor and Chief Division of Abdominal Transplantation Department of Surgery University of North Carolina at Chapel Hill.
Update on the febrile seizure signal after influenza vaccine David Martin, MD, MPH Pharmacovigilance Branch Division of Epidemiology Office of.
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.
IOM Review: VSD Data Sharing Program Melinda Wharton, M.D. National Immunization Program, CDC NVAC Vaccine Safety Subcommittee October 5, 2004.
Severe Acute Respiratory Syndrome (SARS) and Preparedness for Biological Emergencies 27 April 2004 Jeffrey S. Duchin, M.D. Chief, Communicable Disease.
Immunization Safety System- Registry Linkages: Lessons Learned from the Smallpox Vaccination Program John Iskander, David Walker, Roseanne English-Bullard,
DEPARTMENT OF HEALTH AND HUMAN SERVICES An Overview of the Defense Medical Surveillance System The DMSS Project Laura H. Franzke, PhD, MPH National Immunization.
Vaccine Safety Research, Data Access, and Public Trust Findings and Recommendations from IOM NVAC Meeting June 8, 2005 Debra Lappin, J.D. Senior Advisor,
Marianne M. Elliott Office of Research Integrity and Ethics Bureau of Medicine and Surgery U. S Navy.
Uses of the NIH Collaboratory Distributed Research Network Jeffrey Brown, PhD for the DRN Team Harvard Pilgrim Health Care Institute and Harvard Medical.
Pulse Oximetry Screening for Critical Congenital Heart Disease (CCHD): The Wisconsin Experience Region IV Genetics Meeting September 11, 2012 Sharon Fleischfresser.
H1N1 Vaccine Safety Subgroup: Draft Recommendations to NVAC NVAC Teleconference July 27, 2009 Daniel Salmon Vaccine Safety Specialist National Vaccine.
A Perspective on Family Medicine and End-of-Life and Palliative Care Peter Selwyn, M.D., M.P.H. Professor and Chairman Department of Family & Social Medicine.
TM Influenza Vaccine Safety in Children: Data from VAERS John Iskander MD MPH Gina Mootrey DO MPH Penina Haber MPH Roseanne English-Bullard BS.
CLINICAL TRIALS.
The HIPAA Privacy Rule: Implications for Medical Research
National Immunization Conference April 19, 2010
Protective Factors Screening
Systematic Reviews and Medical Policy Determinations
ACIP Feb , 2007 Guillain-Barré Syndrome (GBS) Among Recipients of Meningococcal Conjugate Vaccine (MCV4,Menactra®) Update Oct Jan Robert.
Terri Magruder, MD, MPH Sept. 22, 2017
Robert Ball, M.D., M.P.H., Sc.M. Division of Epidemiology
Pediatric Inactivated Influenza Vaccine Safety VAERS Reports for Trivalent Inactivated Influenza Vaccine (TIV) in Infants/Toddlers Ann McMahon, MD, MS.
Framework for Analysis of Multiple Near-Simultaneous Vaccinations and U.S. Military Hospitalizations Charles Rose, PhD Daniel Payne, PhD, MSPH.
Indiana Traumatic Brain Injury State Plan 2018 – 2023
Updating the National Vaccine Plan: A roadmap for the next decade A National, not Federal, Plan December 11, 2009.
Presentation transcript:

DEPARTMENT OF HEALTH AND HUMAN SERVICES Monitoring Anthrax Vaccine Adverse Events Defense Medical Surveillance System (DMSS) Michael McNeil, MD, MPH National Immunization Program NVAC, June 4 th, 2003

DEPARTMENT OF HEALTH AND HUMAN SERVICES Overview of the DMSS Project  How were the topics selected?  Potential Topics  Criteria for Prioritizing Topics  Timeline  Next Steps

DEPARTMENT OF HEALTH AND HUMAN SERVICES Sources for Topic Selection:  Institute of Medicine (IOM)  Anthrax Vaccine Expert Committee (AVEC)  Vaccine Adverse Event Reporting System (VAERS)  Medical and Public Health Literature  CDC, FDA, DoD  Public Opinion

DEPARTMENT OF HEALTH AND HUMAN SERVICES Possible Topics for Investigation Endocrine SystemIntegument System Diabetes mellitus Rash with mucosal involvement Nervous SystemMusculoskeletal System Peripheral neuropathyJoint disorders Guillain-Barre SyndromeMyositis Demyelinating conditions

DEPARTMENT OF HEALTH AND HUMAN SERVICES Possible Topics for Investigation Cardiovascular System Atrial fibrillation Vasculitis Psychiatric Disorders Mood disorder Other Topics Syndromic illness Loss of duty Death Medical encounters Unintentional injury

DEPARTMENT OF HEALTH AND HUMAN SERVICES Potential Criteria for Prioritizing Topics  Frequency of Occurrence  Feasibility  Severity of Effect  Likelihood of Association  Programmatic Interventions  Public Health Concern

DEPARTMENT OF HEALTH AND HUMAN SERVICES Frequency of Occurrence  Reports from VAERS  Reports from DMSS  Reports from other sources

DEPARTMENT OF HEALTH AND HUMAN SERVICES Feasibility  Well-characterized natural history  Established pathophysiology  Practical issues (e.g., obtaining medical charts)  Basis for making the diagnosis  Subjective (e.g., symptoms)  Objective findings (e.g., laboratory tests)

DEPARTMENT OF HEALTH AND HUMAN SERVICES Feasibility (cont’d)  Universally accepted case-definition  Specificity  Sensitivity  Positive predictive value  Existence of a specific ICD-9 code  Identifiable/available study and comparison groups of adequate size  Ethical concerns

DEPARTMENT OF HEALTH AND HUMAN SERVICES Severity of Effect  Acute vs. chronic course  Impact on functional status and/or quality of life  Life-threatening  Hospitalization

DEPARTMENT OF HEALTH AND HUMAN SERVICES Likelihood of Association or Causation  Published studies – strength of findings  Consistency of findings  Biological plausibility  Temporal association of effect with putative cause  Demonstration of dose-response effect

DEPARTMENT OF HEALTH AND HUMAN SERVICES Programmatic Interventions  Permits screening and possible deferral of AVA recipients  Availability of treatment(s)  Altered use of AVA  Reformulation of vaccine  Change in site, dosage, route of administration, and pre- treatment/site care

DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Concern  Sources of Concern:  AVEC  VHC  CDC  Advocacy groups  News media  Level of Concern  Congress  Data Safety Monitoring Board (DSMB)  IOM  DoD  FDA

DEPARTMENT OF HEALTH AND HUMAN SERVICES Timeline  MOU  Office space  Equipment  Oct. 15 th IOM January 2003 July 2002

DEPARTMENT OF HEALTH AND HUMAN SERVICES Timeline  MOU  Office space  Equipment  Oct. 15 th IOM  Jan. 30th Meeting  Recruitment  Tasks created  Topics selected  Criteria  Committees March 2003 January 2003 July 2002

DEPARTMENT OF HEALTH AND HUMAN SERVICES Timeline  MOU  Office space  Equipment  Oct. 15 th IOM  Jan. 30th Meeting  Recruitment  Tasks created  Topics selected  Criteria  Committees April 2003 January 2003 July 2002 March 2004  Criteria papers (April-May)  Hire Staff (May-June)  Prioritize topics (July)  Protocol (July-Mar)

DEPARTMENT OF HEALTH AND HUMAN SERVICES Timeline for the External Consultative Committee  NVAC Meeting  Select members  Topic papers  Prioritize topics (July – August 2003) August 2003 July 2003 June 2003 March 2004  Protocol Review (March 2004)

DEPARTMENT OF HEALTH AND HUMAN SERVICES Acknowledgements DOD Mark Rubertone John Grabenstein John Brundage Jeff Lange DMSS Staff CDC Ben Schwartz Bruce Tierney Phil Rhodes Stacey Martin Paul Stehr-Green Betsy Cadwell Roseanne English- Bullard Kelly Bell FDA Bob Ball Dale Burwen Jane Woo FOH Wayne Grant Richard Horn AVEC